Jun 2026 (Q2 FY26) — Aug 5, 2026
Paysign Q2 FY26 — Record Revenue and Profitability Driven by Patient Affordability
Read the full callPaysign (PAYS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Paysign earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 28.3 | +48.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 24.8 | +17.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 6.8 | +386.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$15.34 +3.65% · +$0.54
Performance +183.5% 1Y
1Y: $5.41 on 17 Oct 2025 → $15.34. High $15.6 (15 Oct 2026), low $3.18 (19 Mar 2026).
- Previous close
- $14.8
- 52-week range
- $3.18 – $15.6
- One year
- +172.47%
Overview
- Symbol
- PAYS
- Sector
- Industrials
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Paysign earnings calls (PAYS)
Financials
What the filings say
Net profit, year on year: +387% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 16 | 19 | 19 | 22 | 23 | 28 | 28 |
| Operating profit | 1 | 0 | 2 | 1 | 2 | 2 | 7 | 7 |
| Operating margin | 4.5% | 3.0% | 13.4% | 7.5% | 7.3% | 8.2% | 23.8% | 24.8% |
| Profit before tax | 1 | 1 | 3 | 2 | 2 | 2 | 7 | 8 |
| Tax rate | 3.6% | −11.1% | 20.5% | 32.1% | 1.4% | 45.4% | 27.2% | 14.5% |
| Net profit | 1 | 1 | 3 | 1 | 2 | 1 | 5 | 7 |
| EPS ($ per share) | 0.03 | — | 0.05 | 0.03 | 0.04 | — | 0.10 | 0.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 1 | 8 | -1 | -4 | -3 | 4 | 8 | 15 |
| Total liabilities | 27 | 34 | 55 | 71 | 92 | 122 | 149 | 228 |
| Fixed assets | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 |
| Total assets | 36 | 54 | 68 | 84 | 108 | 147 | 179 | 276 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 16 | 17 | 14 | 15 | 25 | 28 | 23 | 52 |
| Cash from investing | -2 | -3 | -3 | -3 | -4 | -7 | -9 | -10 |
| Cash from financing | 0 | 0 | -0 | 0 | 0 | -1 | -0 | 0 |
| Capital expenditure | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -1 |
| Free cash flow | 16 | 16 | 12 | 15 | 25 | 27 | 23 | 51 |
Insider filings
56 filings between Nov 13, 2025 and Oct 9, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.26M
20 sales by 8 insiders
55% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
- 10
- Option exercise — converted options into shares
- 16
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Newcomer Mark | — | $3.02M | Oct 9, 2026 |
| Herman Joan M | — | $2.47M | Sep 16, 2026 |
| Ngo Michael C | — | $1.92M | Sep 9, 2026 |
| Baker Jeffery Bradford | — | $441.6K | Aug 12, 2026 |
| Mina Bruce A | — | $141.9K | Jun 11, 2026 |
| Strobo Robert | — | $109.4K | Dec 12, 2025 |
| Cunningham Bradley Kramer | — | $96.4K | Jun 1, 2026 |
| Turner Matthew Baker | — | $62.6K | Feb 3, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Newcomer Mark CEO | Sale 10b5-1 plan | 50,000 | $766.9K |
| Sep 16, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 38,900 | $456.8K |
| Sep 15, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 21,004 | $260.1K |
| Sep 9, 2026 | Ngo Michael C Chief Innovation Officer | Sale | 79,925 | $1.02M |
| Sep 8, 2026 | Ngo Michael C Chief Innovation Officer | Sale | 70,075 | $900.4K |
| Aug 12, 2026 | Baker Jeffery Bradford Chief Financial Officer | Sale | 35,000 | $441.6K |
| Aug 6, 2026 | Newcomer Mark CEO | Sale 10b5-1 plan | 150,000 | $1.78M |
| Aug 4, 2026 | Triplett Dennis L Director | Option exercise | 20,000 | $0 |
| Aug 4, 2026 | NEWMAN JEFFREY B Director | Option exercise | 20,000 | $0 |
| Aug 4, 2026 | Mina Bruce A Director | Option exercise | 20,000 | $0 |
| Aug 4, 2026 | HENRY DANIEL R Director | Option exercise | 20,000 | $0 |
| Jul 31, 2026 | Cunningham Bradley Kramer Chief Technology Officer | Tax withheld | 22,430 | $201.0K |
| Jul 31, 2026 | Newcomer Mark CEO | Option exercise | 150,000 | $0 |
| Jul 31, 2026 | Lanford Matthew Louis Chief Payments Officer | Tax withheld | 25,185 | $225.7K |
| Jul 31, 2026 | Newcomer Mark CEO | Tax withheld | 59,025 | $528.9K |
| Jul 31, 2026 | Lanford Matthew Louis Chief Payments Officer | Option exercise | 64,000 | $0 |
| Jul 31, 2026 | Strobo Robert Chief Legal Officer | Tax withheld | 25,184 | $225.6K |
| Jul 31, 2026 | Baker Jeffery Bradford Chief Financial Officer | Tax withheld | 28,506 | $255.4K |
| Jul 31, 2026 | Herman Joan M EVP, EFT Operations | Tax withheld | 13,780 | $123.5K |
| Jul 31, 2026 | Baker Jeffery Bradford Chief Financial Officer | Option exercise | 64,000 | $0 |
| Jul 31, 2026 | Strobo Robert Chief Legal Officer | Option exercise | 64,000 | $0 |
| Jul 31, 2026 | Herman Joan M EVP, EFT Operations | Option exercise | 36,000 | $0 |
| Jul 29, 2026 | Newcomer Mark CEO | Sale 10b5-1 plan | 50,000 | $469.0K |
| Jul 16, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 28,000 | $243.4K |
| Jul 15, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 31,904 | $274.3K |
| Jun 30, 2026 | Cunningham Bradley Kramer Chief Technology Officer | Tax withheld | 11,579 | $94.8K |
| Jun 26, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 100,000 | $801.1K |
| Jun 11, 2026 | Mina Bruce A Director | Sale | 10,000 | $71.0K |
| Jun 1, 2026 | Cunningham Bradley Kramer Chief Technology Officer | Sale | 3,000 | $23.4K |
| Jun 1, 2026 | Mina Bruce A Director | Sale | 10,000 | $71.0K |
| Jun 1, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 29,202 | $233.7K |
| May 29, 2026 | Cunningham Bradley Kramer Chief Technology Officer | Sale | 10,000 | $73.0K |
| May 29, 2026 | Baker Jeffery Bradford Chief Financial Officer | Tax withheld | 44,541 | $323.8K |
| May 27, 2026 | Strobo Robert Chief Legal Officer | Tax withheld | 39,235 | $279.0K |
| May 26, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 22,534 | $158.0K |
| May 22, 2026 | Turner Matthew Baker PRES., PATIENT AFFORDABILITY | Tax withheld | 50,681 | $340.6K |
| May 20, 2026 | Newcomer Mark CEO | Tax withheld | 78,701 | $484.0K |
| May 18, 2026 | Cunningham Bradley Kramer Chief Technology Officer | Tax withheld | 12,369 | $72.5K |
| May 18, 2026 | Lanford Matthew Louis Chief Payments Officer | Tax withheld | 12,755 | $74.8K |
| May 13, 2026 | Herman Joan M EVP, Operations | Tax withheld | 6,171 | $36.0K |
| May 8, 2026 | HENRY DANIEL R Director | Award | 20,000 | $0 |
| May 8, 2026 | Triplett Dennis L Director | Award | 20,000 | $0 |
| May 8, 2026 | NEWMAN JEFFREY B Director | Award | 20,000 | $0 |
| May 8, 2026 | Mina Bruce A Director | Award | 20,000 | $0 |
| May 4, 2026 | Herman Joan M EVP, Operations | Sale 10b5-1 plan | 6,667 | $46.7K |
| Mar 31, 2026 | Ngo Michael C Chief Innovation Officer | Tax withheld | 38,664 | $228.1K |
| Feb 28, 2026 | Baker Jeffery Bradford Chief Financial Officer | Tax withheld | 26,055 | $92.5K |
| Feb 28, 2026 | Baker Jeffery Bradford Chief Financial Officer | Option exercise | 60,000 | $0 |
| Feb 3, 2026 | Turner Matthew Baker PRES., PATIENT AFFORDABILITY | Sale | 15,057 | $62.6K |
| Dec 12, 2025 | Strobo Robert Chief Legal Officer | Sale | 20,000 | $109.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Paysign, Inc.
Free account. Everything above stays public.
Write why you follow Paysign, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading